Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URM002
MIFTS: 52

Uremia

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Uremia

About this section

MalaCards integrated aliases for Uremia:

Name: Uremia 12 76 55 44 15 73
Uremia of Renal Origin 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4676
ICD10 33 N19
MeSH 44 D014511
SNOMED-CT 68 44730006
UMLS 73 C0041948
Sources

Summaries for Uremia

About this section
MalaCards based summary : Uremia, also known as uremia of renal origin, is related to hyperparathyroidism and hyperphosphatemia. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and HIF-1 signaling pathway. The drugs Gabapentin and Fexofenadine have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and testes, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 76 Uremia is the condition of having high levels of urea in the blood. Urea is one of the primary... more...

Sources

Related Diseases for Uremia

About this section

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 30.5 CASR EPO PTH TNFRSF11B VDR
2 hyperphosphatemia 30.2 CASR PTH VDR
3 secondary hyperparathyroidism of renal origin 30.2 ALB CASR EPO PTH TNFRSF11B VDR
4 renal osteodystrophy 30.2 CASR PTH TNFRSF11B VDR
5 arteriosclerosis 30.1 CRP INS SPP1
6 arteries, anomalies of 30.0 ALB CRP INS LEP VWF
7 osteomalacia 29.9 CASR PTH VDR
8 bone resorption disease 29.8 PTH SPP1 TNFRSF11B VDR
9 bone disease 29.8 B2M CASR PTH SPP1 TNFRSF11B VDR
10 arthropathy 29.7 B2M CRP TNFRSF11B
11 multiple endocrine neoplasia, type i 29.7 CASR INS PTH
12 sleep apnea 29.7 CRP INS LEP
13 liver disease 29.7 ALB INS LEP TF
14 diabetes mellitus 29.7 ALB CRP EPO INS LEP LPL
15 primary hyperparathyroidism 29.6 ALB CASR PTH VDR
16 analbuminemia 29.6 ALB CRP EPO TF
17 insulin-like growth factor i 29.6 GHR INS LEP
18 pancreatitis 29.6 CASR CRP LPL
19 hyperglycemia 29.5 ALB INS LEP
20 cerebrovascular disease 29.5 CRP INS VWF
21 heart disease 29.4 ALB APOC3 CRP INS LPL VWF
22 nutritional deficiency disease 29.4 ALB CRP EPO LEP TF
23 liver cirrhosis 29.3 ALB LEP RETN TF
24 vascular disease 29.2 ALB CRP INS LPL RETN TNFRSF11B
25 glucose intolerance 29.2 CRP INS LEP LPL RETN
26 hypertension, essential 29.1 ALB CRP INS LEP LPL RETN
27 myocardial infarction 28.9 ALB APOC3 CRP INS RETN VWF
28 chronic kidney failure 28.8 ALB B2M CASR CRP EPO INS
29 coronary heart disease 1 28.8 APOC3 CRP INS LPL RETN VWF
30 kidney disease 28.7 ALB APOC3 B2M CASR CRP EPO
31 diabetes mellitus, noninsulin-dependent 28.3 AHSG ALB APOC3 CRP INS LEP
32 hemolytic-uremic syndrome 11.4
33 nephronophthisis 1 11.2
34 euthyroid sick syndrome 11.1
35 malignant otitis externa 10.3 CRP INS
36 severe nonproliferative diabetic retinopathy 10.3 ALB INS
37 gastrointestinal tuberculosis 10.3 ALB CRP
38 abdominal tuberculosis 10.3 ALB CRP
39 scleredema adultorum 10.3 INS PTH
40 immunodeficiency 43 10.3 ALB B2M
41 pyuria 10.3 ALB CRP
42 fibrogenesis imperfecta ossium 10.2 PTH TNFRSF11B
43 fetal erythroblastosis 10.2 ALB EPO INS
44 hypocalciuric hypercalcemia, familial, type i 10.2 CASR PTH
45 pleural disease 10.2 ALB CRP SPP1
46 hypocalciuric hypercalcemia, familial, type iii 10.2 CASR PTH
47 orthostatic proteinuria 10.2 ALB B2M
48 al amyloidosis 10.2 B2M VWF
49 hemorrhagic fever with renal syndrome 10.2 ALB B2M CRP
50 burns 10.2 CRP INS

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia
Sources

Symptoms & Phenotypes for Uremia

About this section

MGI Mouse Phenotypes related to Uremia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 AHSG ALB B2M CASR CRP EPO
2 cellular MP:0005384 10.35 ALB B2M CASR EPO GHR INS
3 cardiovascular system MP:0005385 10.33 B2M CRP EPO GHR INS LEP
4 growth/size/body region MP:0005378 10.27 AHSG B2M CASR GHR INS LEP
5 hematopoietic system MP:0005397 10.26 B2M CASR EPO GHR INS LEP
6 immune system MP:0005387 10.25 B2M CASR CRP EPO GHR INS
7 endocrine/exocrine gland MP:0005379 10.11 ALB B2M CASR GHR INS LEP
8 mortality/aging MP:0010768 10.1 ALB B2M CASR EPO GHR INS
9 digestive/alimentary MP:0005381 10.07 ALB B2M CASR INS LEP VDR
10 integument MP:0010771 10.06 B2M CASR EPO GHR INS LEP
11 liver/biliary system MP:0005370 9.97 ALB B2M EPO GHR INS LEP
12 limbs/digits/tail MP:0005371 9.91 AHSG EPO GHR LEP PTH TNFRSF11B
13 muscle MP:0005369 9.85 AHSG ALB CASR EPO GHR INS
14 renal/urinary system MP:0005367 9.5 ALB CASR GHR INS LEP SPP1
15 skeleton MP:0005390 9.32 AHSG CASR EPO GHR INS LEP
Sources

Drugs & Therapeutics for Uremia

About this section

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
2
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
3
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
7
Metformin Approved Phase 4 657-24-9 14219 4091
8 tannic acid Approved Phase 4
9
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
10
Liraglutide Approved Phase 4 204656-20-2 44147092
11
Pamidronate Approved Phase 4 40391-99-9 4674
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
13
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
14
Histamine Phosphate Phase 4 51-74-1 65513
15 Histamine Antagonists Phase 4
16 Anti-Allergic Agents Phase 4
17 Histamine H1 Antagonists, Non-Sedating Phase 4
18 Psychotropic Drugs Phase 4,Not Applicable
19 calcium channel blockers Phase 4,Not Applicable
20 Central Nervous System Depressants Phase 4,Not Applicable
21 Anti-Anxiety Agents Phase 4,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
23 Anticonvulsants Phase 4,Not Applicable
24 Tranquilizing Agents Phase 4,Not Applicable
25 Neurotransmitter Agents Phase 4,Not Applicable
26 Calcium, Dietary Phase 4,Not Applicable
27 Analgesics Phase 4,Phase 3,Not Applicable
28 Histamine H1 Antagonists Phase 4
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
30 Hormone Antagonists Phase 4,Phase 2,Not Applicable
31 Hormones Phase 4,Phase 2,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Vitamin B Complex Phase 4
34 Vitamins Phase 4,Phase 2
35 Vitamin B9 Phase 4
36 Micronutrients Phase 4,Phase 2
37 Folate Phase 4
38 Trace Elements Phase 4,Phase 2
39 Hematinics Phase 4
40 Antioxidants Phase 4,Phase 1,Phase 2
41 Protective Agents Phase 4,Phase 1,Phase 2
42 Polymethyl Methacrylate Phase 4
43 Vasodilator Agents Phase 4
44 Hypoglycemic Agents Phase 4,Phase 2
45 Incretins Phase 4
46 Dialysis Solutions Phase 4,Phase 3,Phase 2
47
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
48
Nafamostat Investigational Phase 3 81525-10-2
49 Complement System Proteins Phase 3,Phase 2
50 Analgesics, Non-Narcotic Phase 3

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Probiotics Use in the Chronic Peritoneal Dialysis Patients Unknown status NCT01076426 Phase 4 Pro-biotics
2 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
3 Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events Completed NCT00317005 Phase 4 folate treatment
4 Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
7 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
8 Hannover Dialysis Outcome Study Completed NCT00529139 Phase 4
9 Very Low Protein Diet or Dialysis in Uremic Elderly? Completed NCT00388648 Phase 4 mixture of amino and keto acids
10 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
11 Liraglutide Treatment to Patients With Severe Renal Insufficiency Completed NCT01394341 Phase 4 Liraglutide
12 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
13 STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE Completed NCT00278057 Phase 4 dialysisis with and without glucose in the dialysis
14 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
15 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
16 Erythropoietin in Hemolytic Uremic Syndrome Not yet recruiting NCT03776851 Phase 4 erythropoietin
17 Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Unknown status NCT02976688 Phase 2, Phase 3
18 Nafamostat Efficacy and Safety in Critically Ill Patients(NICE) Unknown status NCT01486485 Phase 3 heparinized saline priming group;nafamostat infusion after heparinized saline priming
19 The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
20 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
21 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
22 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
23 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
24 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
25 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Active, not recruiting NCT02949128 Phase 3
26 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
27 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
28 Effect of SVF Derived MSC in DCD Renal Transplantation Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
29 Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
30 Effect of BM-MSCs in DCD Kidney Transplantation Unknown status NCT02561767 Phase 1, Phase 2 Induction therapy (ATG or Basiliximab);Maintenance therapy (Low-dose CNI + MPA + steroids)
31 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
32 Induction With SVF Derived MSC in Living-related Kidney Transplantation Unknown status NCT02492308 Phase 1, Phase 2 Basiliximab induction
33 Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Unknown status NCT01876017 Phase 1, Phase 2
34 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
35 L-Cysteine in Peritoneal Dialysis Completed NCT02050139 Phase 2
36 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
37 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
38 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
39 Role of Turmeric on Oxidative Modulation in ESRD Patients Completed NCT01906840 Phase 1, Phase 2 Turmeric;placebo
40 Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Completed NCT00309257 Phase 2 ACE I, ATA II and Statins;Benazepril, Valsartan and Fluvastatin
41 Sevelamer in Proteinuric CKD Completed NCT01968759 Phase 2 Sevelamer;Ramipril and Irbesartan
42 A Study in Participants With End-Stage Renal Disease Completed NCT01200290 Phase 2 LY2127399
43 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
44 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
45 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
46 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
47 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
48 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab
49 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2 eculizumab
50 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Recruiting NCT03518203 Phase 2 Eculizumab

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: uremia

Sources

Genetic Tests for Uremia

About this section
Sources

Anatomical Context for Uremia

About this section

MalaCards organs/tissues related to Uremia:

41
Kidney, Bone, Testes, Endothelial, Liver, Monocytes, Heart
Sources

Publications for Uremia

About this section

Articles related to Uremia:

(show top 50) (show all 1075)
# Title Authors Year
1
Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. ( 29304096 )
2018
2
RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. ( 29529595 )
2018
3
Uremia: A historical reappraisal of what happeneda8c. ( 29451473 )
2018
4
Carmelo Giordano (1930-2016): uremia therapy by low protein alimentation and sorbents. ( 29482271 )
2018
5
Risk factors of the peptic ulcer bleeding in aging uremia patients under regular hemodialysis. ( 29778548 )
2018
6
CRP, ILa892 and TNFa89I+ level in patients with uremia receiving hemodialysis. ( 29257244 )
2018
7
Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review. ( 30407278 )
2018
8
Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. ( 30145224 )
2018
9
Evaluation of carotid artery elasticity in patients with uremia by echo tracking. ( 29453675 )
2018
10
Uremia increases QRS duration after β-adrenergic stimulation in mice. ( 29984555 )
2018
11
Depressive Symptoms in Dialysis: Prevalence and Relationship with Uremia-Related Biochemical Parameters. ( 30048984 )
2018
12
Preliminary study of Bim on the early diagnosis and prognosis of the elderly uremia with gastrointestinal nutrition combined with dialysis. ( 30058698 )
2018
13
Uremia induces upregulation of cerebral tissue oxidative/inflammatory cascade, down-regulation of Nrf2 pathway and disruption of blood brain barrier. ( 30093950 )
2018
14
Cannabinoid Hyperemesis Syndrome Masquerading as Uremia: An Educational Case Report. ( 30159161 )
2018
15
Increased electronegativity of high-density lipoprotein in uremia patients impairs its functional properties and is associated with the risk of coronary artery disease. ( 30278357 )
2018
16
Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. ( 30301260 )
2018
17
Homocysteine Aggravates Intestinal Epithelial Barrier Dysfunction in Rats with Experimental Uremia. ( 30336454 )
2018
18
Serum and Lipoprotein Particle miRNA Profile in Uremia Patients. ( 30400676 )
2018
19
Two-dimensional speckle tracking to image ventricular-arterial coupling in uremia. ( 30411403 )
2018
20
MicroRNA-142-3p improves vascular relaxation in uremia. ( 30453118 )
2018
21
Efficacy of linalool to ameliorate uremia induced vascular calcification in wistar rats. ( 30466616 )
2018
22
Influence of colonic dialysis using Gubenxiezhuo on the distribution of gut microflora in uremia rats. ( 30536550 )
2018
23
WISP1 silencing confers protection against epithelial-mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/β-catenin signaling pathway in uremia. ( 30556898 )
2018
24
The function of the parathyroid oxyphil cells in uremia: still aA mystery? ( 29055426 )
2017
25
Evaluation of the different surgical parathyroidectomieson secondary hyperparathyroidism in uremia patients. ( 29205012 )
2017
26
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28376076 )
2017
27
Serpiginous cranial arterial calcification in uremia. ( 28972106 )
2017
28
Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. ( 28680087 )
2017
29
Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. ( 28523279 )
2017
30
"Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia. ( 28524108 )
2017
31
Sudden bilateral vision loss as the sole manifestation of posterior reversible encephalopathy syndrome from acute uremia: Clinical case report. ( 28682904 )
2017
32
Asymptomatic Brain Edema after Hemodialysis Initiation in a Patient with Severe Uremia. ( 28553356 )
2017
33
Uremia ( 28722889 )
2017
34
Uremia does not affect neointima formation in mice. ( 28747676 )
2017
35
Simultaneous liver, pancreas-duodenum and kidney transplantation in a patient with hepatitis B cirrhosis, uremia and insulin dependent diabetes mellitus. ( 29259387 )
2017
36
Persistence of Vascular Calcification after Reversal of Uremia. ( 27939134 )
2017
37
Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction. ( 28605780 )
2017
38
Skin Blood Flow and Vascular Endothelium Function in Uremia. ( 29056167 )
2017
39
Influence of SPK with Enteric Drainage on the Pancreatic Exocrine Function in Diabetic Patients with Uremia. ( 29138633 )
2017
40
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 29040261 )
2017
41
A History of Uremia Research. ( 29056163 )
2017
42
Research progress about effects of myocardial enzyme and troponin on uremia with acute left ventricular failure. ( 28338189 )
2017
43
CORRIGENDUM: Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28832560 )
2017
44
Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. ( 28341272 )
2017
45
Uremia modulates the phenotype of aortic smooth muscle cells. ( 28107707 )
2017
46
Proceedings of the Ninth International Congress of Uremia Research and Toxicity. ( 29056162 )
2017
47
Risk factors for cardiovascular disease in children on chronic hemodialysis - Uremia related (non-traditional) risk factors, part II. ( 29350892 )
2017
48
Bilateral rectal sheath hematomas after low-molecular weight heparin treatment in uremia. ( 28330422 )
2017
49
The Evolving Patterns of Uremia: Unmet Clinical Needs in Dialysis. ( 28910786 )
2017
50
Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia. ( 28050009 )
2017
Sources

Variations for Uremia

About this section
Sources

Expression for Uremia

About this section
Search GEO for disease gene expression data for Uremia.
Sources

Pathways for Uremia

About this section

Pathways related to Uremia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Parathyroid hormone synthesis, secretion and action 37
11.68 CASR PTH VDR
2
HIF-1 signaling pathway 37
11.63 EPO INS TF
3
Adipogenesis 1
11.38 INS LEP LPL RETN
4
Endochondral Ossification 1
11.36 GHR PTH SPP1
5
HIF-1-alpha transcription factor network 1
11.31 EPO LEP TF
6
Differentiation Pathway 1
11.11 EPO INS TF
7
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
10.92 PTH SPP1 VDR
8
Osteoclast Signaling 1
10.7 SPP1 TNFRSF11B
9
Osteoblast Signaling 1
10.58 PTH TNFRSF11B
10
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.58 PTH SPP1 TNFRSF11B VDR
11
Vitamin D Metabolism 1
10.4 PTH VDR
Sources

GO Terms for Uremia

About this section

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 AHSG ALB APOC3 B2M CRP EPO
2 cell surface GO:0009986 9.73 B2M CASR EPO GHR LPL TF
3 secretory granule lumen GO:0034774 9.63 AHSG INS TF
4 endoplasmic reticulum lumen GO:0005788 9.63 AHSG ALB B2M INS SPP1 TF
5 extracellular region GO:0005576 9.53 AHSG ALB APOC3 B2M CRP EPO
6 platelet alpha granule lumen GO:0031093 9.5 AHSG ALB VWF
7 chylomicron GO:0042627 9.4 APOC3 LPL
8 HFE-transferrin receptor complex GO:1990712 9.37 B2M TF
9 extracellular exosome GO:0070062 10.03 AHSG ALB APOC3 B2M RETN SPP1

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.92 AHSG ALB SPP1 TF
2 response to drug GO:0042493 9.88 B2M LPL PTH TNFRSF11B
3 cellular calcium ion homeostasis GO:0006874 9.74 CASR PTH VDR
4 response to nutrient GO:0007584 9.72 EPO LEP TNFRSF11B
5 skeletal system development GO:0001501 9.71 AHSG PTH TNFRSF11B VDR
6 regulation of signaling receptor activity GO:0010469 9.7 EPO INS LEP PTH RETN SPP1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 EPO GHR LEP
8 high-density lipoprotein particle remodeling GO:0034375 9.62 ALB APOC3
9 iron ion transport GO:0006826 9.61 B2M TF
10 negative regulation of lipid catabolic process GO:0050995 9.61 APOC3 INS
11 positive regulation of glycogen biosynthetic process GO:0045725 9.6 INS PTH
12 positive regulation of insulin receptor signaling pathway GO:0046628 9.59 INS LEP
13 hormone metabolic process GO:0042445 9.58 GHR LEP
14 intestinal absorption GO:0050892 9.56 LEP VDR
15 platelet degranulation GO:0002576 9.56 AHSG ALB TF VWF
16 negative regulation of blood vessel diameter GO:0097756 9.54 CRP INS
17 retina homeostasis GO:0001895 9.54 ALB B2M TF
18 negative regulation of lipid storage GO:0010888 9.52 CRP LEP
19 chylomicron remodeling GO:0034371 9.49 APOC3 LPL
20 cellular response to iron ion GO:0071281 9.48 B2M TF
21 negative regulation of feeding behavior GO:2000252 9.46 INS RETN
22 response to fibroblast growth factor GO:0071774 9.43 CASR PTH
23 regulation of iron ion import GO:1900390 9.32 B2M TF
24 acute-phase response GO:0006953 9.26 AHSG CRP EPO INS
25 cellular protein metabolic process GO:0044267 9.1 AHSG ALB B2M INS SPP1 TF

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB B2M CRP GHR INS VWF
2 hormone activity GO:0005179 9.02 EPO INS LEP PTH RETN
3 peptide hormone receptor binding GO:0051428 8.96 LEP PTH
Sources

Sources for Uremia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....